VANCOUVER, British Columbia, Dec. 05, 2017 (GLOBE NEWSWIRE) — Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) announces its research arm, Cannevert Therapeutics Ltd. (“CTL”) has signed a Material Transfer Agreement with the Institute for Medical Cannabis (“IMC”) Corporation of Puerto Rico. IMC will provide Cannevert with specific cannabis strains for upcoming human studies in the US territory.
IMC is the first licensed medical cannabis company under the State Department Medical Cannabis Health Code to supply a variety of the high quality medical cannabis products for the medical community. It has a state of the art facility in Ponce that provides cultivation, extraction, formulation, multiple forms of production, and research using the best, award winning strains, technology and processes in the industry.
IMC operates in a 44,000-square-foot building with 15,000 square feet of indoor cannabis under lights with an additional 1,800 square feet of ISO
... read more at: https://globenewswire.com/news-release/2017/12/05/1228864/0/en/Veritas-Research-Arm-Cannevert-Signs-a-Material-Transfer-Agreement-with-the-Institute-for-Medical-Cannabis-of-Puerto-Rico.html